|

Galvokimig Clinical Trials

1 actively recruiting trial across 1 location

Also known as: UCB9741

Pipeline

Phase 2: 1

Top Sponsors

  • UCB Biopharma SRL1

Indications

  • Chronic Obstructive Pulmonary Disease With Chronic Bronchitis1
  • COPD1

Boerne, Texas1 trial

A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis

Copd01 50001

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.